Tema Etfs LLC Boosts Bristol Myers Squibb Stake by 25%

Investment firm increases holdings in pharmaceutical giant to $6.89 million

Apr. 2, 2026 at 10:23am

Got story updates? Submit your updates here. ›

Tema Etfs LLC, an investment management firm, increased its stake in Bristol Myers Squibb Company (NYSE:BMY) by 25% during the fourth quarter, according to a recent SEC filing. The firm now owns 127,759 shares of the biopharmaceutical company's stock, valued at $6.89 million.

Why it matters

Bristol Myers Squibb is one of the world's leading pharmaceutical companies, with a focus on oncology, hematology, immunology, and specialty drugs. Tema Etfs' increased investment signals confidence in the company's future growth and product pipeline.

The details

Tema Etfs LLC acquired an additional 25,521 shares of Bristol Myers Squibb during the fourth quarter, bringing its total holdings to 127,759 shares. The investment firm's stake in the company is now valued at $6.89 million, up from $5.51 million in the previous quarter.

  • Tema Etfs LLC increased its stake in Bristol Myers Squibb during the fourth quarter of 2025.

The players

Tema Etfs LLC

An investment management firm that has increased its holdings in Bristol Myers Squibb Company.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases.

Got photos? Submit your photos here. ›

The takeaway

Tema Etfs' increased investment in Bristol Myers Squibb suggests the firm sees strong growth potential in the pharmaceutical company's product pipeline and future prospects.